Sermorelin FAQ: Common Questions Answered

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). After subcutaneous injection, it binds to GHRH receptors on cells in the anterior pituitary, triggering a pulsatile release of human growth hormone. That growth hormone then stimulates the liver to produce IGF-1, the downstream mediator associated with lean mass, fat metabolism, sleep quality, and cellular repair. Because sermorelin acts upstream of the pituitary rather than bypassing it, the somatostatin feedback axis remains intact and the pituitary self-limits output based on circulating GH levels.

Synthetic HGH (recombinant somatropin) bypasses the pituitary and delivers growth hormone directly into circulation. It produces faster and larger IGF-1 increases but costs $600 to $2,000 per month and carries higher rates of fluid retention, carpal tunnel syndrome, and insulin resistance. Sermorelin preserves the somatostatin feedback loop, so the pituitary moderates output and supraphysiologic GH levels are less likely. For adults with age-related rather than pathologic GH decline, sermorelin is the more appropriate first-line option.

The original sermorelin product (Geref) held FDA approval and was voluntarily withdrawn in 2008 for commercial reasons, not safety. Today, sermorelin is prescribed as a compounded formulation under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Compounded sermorelin is not FDA-approved as a finished drug product, but it can be legally prescribed by a licensed physician and dispensed by a state-licensed or FDA-registered compounding pharmacy.

No. Sermorelin is a prescription-only medication in the United States. Any platform selling it without a physician consultation and prescription is not operating within federal law. This includes vendors offering research-grade peptides, which are not manufactured to the sterility standards required for human injection.

The primary candidates are adults over 30 with symptomatic age-related growth hormone decline: reduced lean mass, increased visceral adiposity, disrupted slow-wave sleep, low energy, or slow post-exercise recovery. A baseline IGF-1 test provides a measurable reference point for evaluating whether treatment is indicated and for tracking response over time. Sermorelin is contraindicated in patients with active malignancy, known pituitary tumors, proliferative diabetic retinopathy, or carpal tunnel syndrome.

The most common effects are injection site reactions, flushing, headache, and lightheadedness (all dose-related and most pronounced during the first few weeks). Water retention and transient joint stiffness occur in some patients at doses above 250 mcg and generally resolve with dose reduction. Because the somatostatin axis remains active, GH oversaturation and the risks associated with exogenous HGH are not a clinical concern at therapeutic sermorelin doses.

Sermorelin should not be used in patients with active malignancy, known pituitary tumors, proliferative diabetic retinopathy, pregnancy, or severe carpal tunnel syndrome. Patients on glucocorticoids or thyroid medications may need dose adjustments due to GH axis sensitivity interactions. Untreated hypothyroidism should be resolved before starting sermorelin. Thyroid hormone is required for a normal growth hormone response, and sermorelin is less effective when thyroid function is impaired.

Yes. A baseline IGF-1 panel is required before prescribing. IGF-1 is the primary downstream marker of GH axis activity and the key measure of whether treatment is clinically indicated. Providers that prescribe sermorelin without ordering labs first are skipping the data point that determines whether the medication is appropriate for a given patient. A follow-up IGF-1 test at 90 days is also standard to assess dose response.

Sermorelin is injected subcutaneously, typically into the periumbilical abdomen or lateral thigh. A 29 to 31 gauge insulin syringe is used. The injection is administered at bedtime to align with the natural growth hormone pulse that occurs during slow-wave sleep. Standard starting doses run 100 to 200 mcg once daily, with titration to 200 to 300 mcg based on 90-day IGF-1 results and symptom response.

Add bacteriostatic water to the lyophilized (freeze-dried) sermorelin vial as directed on the label. Swirl gently and do not shake. Store reconstituted vials refrigerated and use within 30 days. Draw the prescribed volume based on your concentration, typically 1 mg/mL. Most programs include detailed reconstitution instructions and injection supplies with the first shipment.

Bedtime is the standard timing. Growth hormone secretion peaks naturally during slow-wave sleep, and administering sermorelin at bedtime amplifies this pulse. Inject on an empty stomach or at least two hours after eating. Carbohydrate-heavy meals raise insulin levels, which impairs the growth hormone response to sermorelin.

Most programs start at 100 mcg for weeks 1 to 4 to assess tolerance, then titrate to 150 to 200 mcg through week 12, and adjust to 200 to 300 mcg based on 90-day IGF-1 results. Maintenance dosing is physician-guided, often on a 5-days-on / 2-days-off schedule to preserve pituitary sensitivity. Combination protocols with ipamorelin or CJC-1295 follow different titration patterns and need more frequent physician oversight than monotherapy.

Compounded sermorelin through a telehealth provider runs $115 to $300 per month depending on dose, protocol complexity, and whether labs are bundled. Entry-level monotherapy programs start around $115 to $150 per month. Combination stacks with ipamorelin or CJC-1295 range from $200 to $350 per month. Programs that advertise a low entry price often add consultation fees, lab costs, and shipping separately.

Standard health insurance does not cover compounded sermorelin. Most telehealth sermorelin programs are cash-pay. HSA and FSA funds are accepted by most of the providers reviewed on this site, which effectively reduces the after-tax cost by 25 to 35 percent depending on your tax bracket. Some providers accept credit cards through medical financing platforms.

This varies by provider. Some programs bundle the medication, consultation fees, and lab monitoring into a single monthly rate. Others bill the consultation, lab work, and medication separately, making the all-in cost significantly higher than the advertised price. Before signing up, confirm whether lab fees, shipping, and follow-up consultations are included in the plan price or billed additionally.

Six markers define a quality program: baseline IGF-1 testing required before prescribing, a board-certified physician supervising the protocol, a 503A or 503B-registered compounding pharmacy, a 90-day follow-up lab panel included in the program, all-in pricing published before any consultation, and a clear cancellation policy. Providers that check all six consistently produce better patient outcomes and fewer surprise costs.

A 503A pharmacy compounds medications for individual patient prescriptions and is regulated by the state board of pharmacy. A 503B outsourcing facility is registered with the FDA, operates under stricter quality controls, and can produce larger batches. Both are legal sources for compounded sermorelin. 503B is the higher standard and is preferred for consistent peptide potency and sterility.

Yes, with the right criteria in place. Sermorelin is self-administered at home and monitoring is lab-based rather than in-person, so the telehealth model is well-suited to this medication. The key requirement is that a licensed physician reviews your labs and supervises your protocol. Programs staffed only by nurse practitioners or health coaches do not meet the clinical standard for prescribing a hormone-modulating medication.

Avoid providers that do not require a baseline IGF-1 panel, cannot name their compounding pharmacy or confirm 503A or 503B registration, have no physician involved in the prescribing process, offer no follow-up labs after 90 days, hide pricing until after a consultation call, or have no published refund or cancellation policy. Any program that makes specific claims about weight loss or muscle gain results is also a concern.

Most patients notice improved sleep quality and energy within weeks 2 to 4. Body composition changes begin to appear between months 3 and 6, when IGF-1 levels approach a new steady state. Physicians check IGF-1 at the 90-day mark to confirm dose response and adjust the protocol. A full 6-month cycle is the clinical standard because sermorelin restores GH secretion gradually rather than delivering exogenous hormone acutely.

Research and patient reports indicate improvements in sleep quality, reduced body fat (particularly visceral fat), increased lean mass, and better post-exercise recovery in adults who complete a full protocol. The degree of change depends on baseline IGF-1, dose adequacy, sleep quality, protein intake, and resistance training volume. Sermorelin does not produce overnight changes. It is intended to support a physiologic process that declines with age, and the timeline for measurable change reflects that gradual mechanism.

GH pulse frequency begins declining within one to two weeks of stopping. IGF-1 levels fall gradually over the following month. Patients who maintain resistance training and adequate protein intake retain significantly more of their body composition gains than those who do not. The pituitary is not suppressed by sermorelin use, so the GH axis retains its ability to respond to future treatment. Many patients transition to a lower-dose maintenance cycle rather than stopping entirely.

The minimum meaningful treatment period is 5 to 6 months, which is how long it takes for IGF-1 to stabilize at a therapeutic level and for body composition changes to become measurable. Many patients continue for 12 months or longer. Long-term protocols typically use a 5-days-on / 2-days-off cycle to maintain pituitary sensitivity. Duration and cycling decisions should be made with your prescribing physician based on 90-day lab results.